Russian Heart Failure Journal 2015year New possibilities in determining efficacy of drug therapy and prognosis for cardiovascular complications in chronic heart failure


To access this material please log in or register

Register Authorize
2015/№3

New possibilities in determining efficacy of drug therapy and prognosis for cardiovascular complications in chronic heart failure

Tregubov V. G.1, Kanorsky S. G.2, Pokrovsky V. M.2
1 – State Budgetary Institution of Health Care, “Territorial Clinical Hospital #2” of the Krasnodar Territory Ministry of Health Care, Krasnykh Partizan 6, Bldg, 2, Krasnodar 350012
2 – State Budgetary Educational Institution of Higher Professional Education, “Kuban State Medical University” of the RF Ministry of Health Care, Sedina 4, Krasnodar 350063

Keywords: CHF, cardiovascular complications, cardio-respiratory synchronism, regulatory-adaptive status

DOI: 10.18087/rhfj.2015.3.2090

Background. Despite improvements in traditional pharmacotherapy and methods of instrumental diagnostics, CHF remains an important issue of medicine and society. In clinical practice, insufficient attention has been paid to the functional status of the body, the reserve of its regulatory and adaptive reactions designed for maintaining the homeostasis. A method of quantifying the regulatory-adaptive status (RAS) would be appropriate for determination of drug efficacy and prediction of cardiovascular complications in CHF. Aim. To establish significance of quantifying the RAS in determination of drug efficacy and risk of cardiovascular complications in CHF. Materials and methods. 100 patients with essential hypertension and/or IHD associated with FC III CHF and impaired left ventricular systolic function participated in the study. Patients receiving a multimodality treatment (quinapril, torasemide, spironolactone) were randomized to two groups. The first group consisted of 56 patients (aged 57.5±21.7) receiving metoprolol succinate 59.1±12.1 mg / day; the second group included 44 patients (aged 57.1±21.4) receiving ivabradine 12.1±4.6 mg / day. Cardio-respiratory synchronism test (for quantitative evaluation of RAS), EchoCG, treadmill metrics, plasma level of N-terminal pro-brain natriuretic hormone, and 6-min walk test were performed at baseline and in 6 months. Cardiovascular complications were analyzed for the next 2 months of the monitored drug therapy. Results. Either regimen of multimodality therapy with metoprolol succinate or ivabradine equally improved the structure and function status of the myocardium, increased exercise tolerance, and reduced neurohumoral hyperactivation. In this process, the benefit of ivabradine regimen for the RAS was greater. Clinical efficacy of the pharmacotherapy was comparable in both groups; incidences of hospitalization for decompensated CHF, ischemic stroke, MI, and cardiovascular fatality did not differ. When the baseline RAS was low and unsatisfactory, the incidence of cardiovascular complications was higher. The originally unsatisfactory RAS was associated with increased risk of sudden cardiac death. Conclusion. The RAS, as an unbiased index for severity of structure and function disorders and intensity of neurohumoral hyperactivation and autonomic dysfunction, can be used for determination of drug efficacy and prediction of cardiovascular complications in patients with CHF.
  1. Liu L., Eisen H. J. Epidemiology of heart failure and scope of the problem. Cardiol Clin. 2014;32 (1):1–8, vii.
  2. Braunwald E. Heart failure. JACC Heart Fail. 2013;1 (1):1–20.
  3. Wu L., Jiang Z., Li C., Shu M. Prediction of heart rate variability on cardiac sudden death in heart failure patients: a systematic review. Int. J. Cardiol. 2014;174 (3):857–860.
  4. Wellens H. J. J., Schwartz P. J., Lindemans F. W., Buxton A. E., Goldberger J. J., Hohnloser S. H., et al. Risk stratification for sudden cardiac death: current status and challenges for the future. Eur. Heart J. 2014;35 (25):1642–1651.
  5. Allen L. A., Magid D. J., Gurwitz J. H., Smith D. H., Goldberg R. J., Saczynski J., et al. Risk factors for adverse outcomes by left ventricular ejection fraction in a contemporary heart failure population. Circ Heart Fail. 2013;6 (4):635–646.
  6. Cooney M. T., Vartiainen E., Laatikainen T., Laakitainen T., Juolevi A., Dudina A., et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am. Heart J. 2010;159 (4):612–619.e3.
  7. Zhang X., Ma L.‑L., Yao D.‑K., Wang L.‑X. Prediction values of T wave alternans for sudden cardiac death in patients with chronic heart failure: a brief review. Congest Heart Fail. 2011;17 (3):152–156.
  8. Fonarow G. C. Clinical risk prediction tools in patients hospitalized with heart failure. Rev Cardiovasc Med. 2012;13 (1):e14 – e23.
  9. Garbi M., McDonagh T., Cosyns B., Bucciarelli-Ducci C., Edvardsen T., Kitsiou A., et al. Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. Eur Heart J Cardiovasc Imaging. 2015;16 (2):147–153.
  10. Arena R., Cahalin L. P., Borghi-Silva A., Phillips S. A. Improving functional capacity in heart failure: the need for a multifaceted approach. Curr. Opin. Cardiol. 2014;29 (5):467–474.
  11. Покровский В. М. Формирование ритма сердца в организме человека и животных. – Краснодар. «Кубань-Книга», 2007. – 143 с.
  12. Покровский В. М., Пономарев В. В., Артюшков В. В. Система для определения сердечно-дыхательного синхронизма у человека.: пат. 86860 USA. – Россия, 2009.
  13. Покровский В. М. Сердечно-дыхательный синхронизм в оценке регуляторно-адаптивных возможностей организма. – Краснодар. «Кубань-Книга», 2010. – 244 с.
  14. Lang R. M., Bierig M., Devereux R. B., Flachskampf F. A., Foster E., Pellikka P. A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18 (12):1440–1463.
  15. Васюк Ю. А. Руководство по функциональной диагностике в кардиологии. – Москва. Практическая медицина, 2012. – 162 с.
  16. Oremus M., Don-Wauchope A., McKelvie R., Santaguida P. L., Hill S., Balion C., et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev. 2014;19 (4):471–505.
  17. Borg G. A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14 (5):377–381.
  18. Реброва О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. 3-е изд. – Москва. МедиаСфера, 2006. – 312 с.
  19. Mozaffarian D., Benjamin E. J., Go A. S., Arnett D. K., Blaha M. J., Cushman M., et al. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation. 2015;131 (4):e29 – e322.
  20. Braunschweig F., Cowie M. R., Auricchio A. What are the costs of heart failure? Europace. 2011;13 Suppl 2ii13 – ii17.
  21. Azad N., Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11 (4):329–337.
  22. Stewart S., MacIntyre K., Hole D. J., Capewell S., McMurray J. J. More «malignant» than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail. 2001;3 (3):315–322.
  23. Shiga T., Kasanuki H. Drug therapy for ventricular tachyarrhythmia in heart failure. Circ. J. 2007;71 Suppl AA90 – A96.
  24. Yancy C. W., Jessup M., Bozkurt B., Butler J., Casey D. E., Drazner M. H., et al. 2013 ACCF / AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013;62 (16):e147 – e239.
  25. Ambrosy A. P., Gheorghiade M., Chioncel O., Mentz R. J., Butler J. Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. Curr Heart Fail Rep. 2014;11 (4):416–427.
  26. McMurray J. J. V. Clinical practice. Systolic heart failure. N. Engl. J. Med. 2010;362 (3):228–238.
  27. Shen M. J., Zipes D. P. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ. Res. 2014;114 (6):1004–1021.
  28. Покровский В. М., Абушкевич В. Г., Дашковский А. И., Шапиро С. В. Возможность управления ритмом сердца посредством произвольного изменения частоты дыхания. Доклады академии наук.;283 (3):738–740.
  29. Трегубов В. Г., Покровский В. М., Канорский С. Г. Коли­чественная оценка регуляторно-адаптивного статуса в определении тяжести хронической сердечной недостаточности. Клиническая медицина. 2012;90 (8):32–35.
Tregubov V. G., Kanorsky S. G., Pokrovsky V. M. New possibilities in determining efficacy of drug therapy and prognosis for cardiovascular complications in chronic heart failure. Russian Heart Failure Journal. 2015;16 (3):145–152

To access this material please log in or register

Register Authorize
Ru En